CVS
CVS HEALTH Corp
$95.93
+1.17%
$121.0B
No data for this timeframe.
Vol
Market Cap$121.0B
Cap SizeLarge Cap
Analyst ConsensusStrong Buy (82%)
Inst. Holders14 funds
Inst. Value$23.6B
Inst. Activity1 buys / 2 sells
Insider Activity0B / 5S
Insider Net $-$338.0M
Reddit Sentiment61° Warm
SEC Reports10
Congressional5 trades
Exchange NYSE·Sector Retail-Drug Stores and Proprietary Stores·Inc. DE·CIK 0000064803·Prev Close $94.82
Recent Activity
Jun 5, 2026
short_volume
Short Volume: CVS — 60.7% short (2.1M / 3.5M)
Short: 2,121,404 | Exempt: 39,247 | TRF Vol: 3,496,539 | Short Ratio: 60.7% | Off-exchange volume (d
Jun 3, 2026
SEC
The court denied Epic's motions to dismiss in eight of eleven complaints in the Generic Pharmaceuticals MDL, allowing an
COURT-RULING — Impact 3/10
May 31, 2026
Insider
Compton-Phillips Amy sold 7,618 shares
EVP, Chief Medical Officer @ $90.98 ($693.1K)
May 31, 2026
Insider
Newman Brian sold 2,478 shares
EVP, Chief Financial Officer @ $90.98 ($225.4K)
May 28, 2026
SEC
A Florida federal magistrate judge granted a motion to remand a slip-and-fall case against a CVS store back to state cou
COURT-RULING — Impact 2/10
May 22, 2026
SEC
CVS Health filed an automatic shelf registration (S-3ASR) to register an indeterminate amount of debt securities (senior
S-3ASR — Impact 3/10
May 21, 2026
Insider
ROBBINS LARRY sold 370,462 shares
Director @ $93.45 ($34.6M)
Inst.
NORGES BANK — NEW
20,996,288 shares ($1.7B)
Price Targets
$103.04
+7.4% upside
Buy
Current $95.93
Low $79.00
Median $104.50
High $140.00
26 analysts
$79.00
$140.00
Analyst Ratings
8Strong Buy
19Buy
6Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Jun 4, 2026 | Morgan Stanley | MAINTAIN | Overweight → Overweight |
| Jun 1, 2026 | Truist Securities | MAINTAIN | Buy → Buy |
| May 26, 2026 | Barclays | MAINTAIN | Overweight → Overweight |
| May 20, 2026 | Mizuho | MAINTAIN | Outperform → Outperform |
| May 14, 2026 | Morgan Stanley | MAINTAIN | Overweight → Overweight |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current FY | $7.43 ▲ +3.8% | $7.35 — $7.65 | 10% YoY | 23 |
| Current Q | $1.83 ▲ +2.0% | $1.48 — $1.94 | 1% YoY | 20 |
| Next Q | $1.71 ▼ -5.8% | $1.56 — $1.90 | 7% YoY | 20 |
| Next FY | $8.37 ▲ +2.0% | $8.07 — $8.80 | 13% YoY | 27 |
Latest Reports
NEUTRAL
COURT-RULING
3/10
The court denied Epic's motions to dismiss in eight of eleven complaints in the Generic Pharmaceuticals MDL, allowing an
Jun 3, 2026
NEUTRAL
COURT-RULING
2/10
A Florida federal magistrate judge granted a motion to remand a slip-and-fall case against a CVS store back to state cou
May 28, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| VANGUARD GROUP INC | $9.6B | — |
| DODGE & COX | $5.0B | — |
| FMR LLC | $3.3B | ADD |
| NORGES BANK | $1.7B | NEW |
| MORGAN STANLEY | $1.6B | — |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| May 31, 2026 | Compton-Phillips Amy | F | $693.1K |
| May 31, 2026 | Newman Brian | F | $225.4K |
| May 21, 2026 | ROBBINS LARRY | SELL | $34.6M |
| May 21, 2026 | ROBBINS LARRY | SELL | $35.3M |
| May 21, 2026 | AGUIRRE FERNANDO | D | $146.1K |
Reddit Sentiment
61°
Warm
Bearish
Neutral
Bullish
Congressional Trades
4 members: 3 buys, 2 sells
| Member | Party | Type | Amount |
|---|---|---|---|
| Ro Khanna | D | BUY | $1,001 - $15,000 |
| Michael McCaul | R | BUY | $15,001 - $50,000 |
| John Boozman | R | BUY | $1,001 - $15,000 |
14 institutional holders with $23.6B total value (296,943,305 shares) as of 2025-Q4. Top holders: VANGUARD, DODGE, FMR. Net selling activity: 2 institutions trimmed/exited vs 1 added.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | VANGUARD GROUP INC | 120,709,530 | $9.6B | 40.7% | — |
| 2 | DODGE & COX | 62,509,988 | $5.0B | 21.1% | — |
| 3 | FMR LLC | 41,017,981 | $3.3B | 13.8% | ADD +47.6% |
| 4 | NORGES BANK | 20,996,288 | $1.7B | 7.1% | NEW |
| 5 | MORGAN STANLEY | 20,373,774 | $1.6B | 6.9% | — |
| 6 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 13,857,346 | $1.1B | 4.7% | NEW |
| 7 | BANK OF AMERICA CORP /DE/ | 9,419,636 | $747.5M | 3.2% | — |
| 8 | WELLS FARGO & COMPANY/MN | 7,066,463 | $560.8M | 2.4% | DOUBLED +100.0% |
| 9 | ARIEL INVESTMENTS, LLC | 825,092 | $65.5M | 0.3% | ADD +50.6% |
| 10 | Hillman Capital Management, Inc. | 71,685 | $5.7M | 0.0% | — |
| 11 | TWO SIGMA INVESTMENTS, LP | 22,692 | $1.8M | 0.0% | NEAR_EXIT -98.7% |
| 12 | Tweedy, Browne Co LLC | 12,085 | $959.1K | 0.0% | DOUBLED +104.6% |
| 13 | Cullen Capital Management, LLC | 4,745 | $376.6K | 0.0% | TRIM -26.5% |
| 14 | Olstein Capital Management, L.P. | 56,000 | $4.4K | 0.0% | TRIM -30.0% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| NORGES BANK | NEW | — | 20,996,288 | — | $1.7B | 2025-Q4 |
| Cullen Capital Management, LLC | TRIM | 6,455 | 4,745 | -26.5% | $376.6K | 2025-Q4 |
| RENAISSANCE TECHNOLOGIES LLC | EXIT | 160,900 | 0 | -100.0% | $0.00 | 2025-Q4 |
| RENAISSANCE TECHNOLOGIES LLC | TRIM | 582,853 | 160,900 | -72.4% | $12.1M | 2025-Q3 |
| Tweedy, Browne Co LLC | DOUBLED | 5,061 | 10,357 | +104.6% | $780.8K | 2025-Q3 |
| Cullen Capital Management, LLC | NEW | — | 6,455 | — | $486.6K | 2025-Q3 |
| NORGES BANK | EXIT | 19,696,987 | 0 | -100.0% | $0.00 | 2025-Q3 |
| FMR LLC | ADD | 30,893,511 | 45,610,230 | +47.6% | $3.1B | 2025-Q2 |
| NORGES BANK | NEW | — | 19,696,987 | — | $1.4B | 2025-Q2 |
| RENAISSANCE TECHNOLOGIES LLC | DOUBLED | 50,000 | 582,853 | +1065.7% | $40.2M | 2025-Q2 |
| Tweedy, Browne Co LLC | NEW | — | 5,061 | — | $349.1K | 2025-Q2 |
| Olstein Capital Management, L.P. | TRIM | 110,000 | 77,000 | -30.0% | $5.3K | 2025-Q2 |
| Mawer Investment Management Ltd. | EXIT | 936,444 | 0 | -100.0% | $0.00 | 2025-Q2 |
| WELLS FARGO & COMPANY/MN | DOUBLED | 3,262,376 | 6,525,936 | +100.0% | $442.1M | 2025-Q1 |
| RENAISSANCE TECHNOLOGIES LLC | NEW | — | 50,000 | — | $3.4M | 2025-Q1 |
| TWO SIGMA INVESTMENTS, LP | NEAR_EXIT | 1,709,465 | 22,694 | -98.7% | $1.5M | 2025-Q1 |
| NORGES BANK | EXIT | 18,702,928 | 0 | -100.0% | $0.00 | 2025-Q1 |
| NORGES BANK | ADD | 14,435,014 | 18,702,928 | +29.6% | $839.6M | 2024-Q4 |
| UBS Group AG | ADD | 6,713,557 | 10,631,341 | +58.4% | $477.2M | 2024-Q4 |
| ARIEL INVESTMENTS, LLC | ADD | 616,807 | 928,626 | +50.6% | $41.7M | 2024-Q4 |
| Olstein Capital Management, L.P. | TRIM | 165,000 | 123,000 | -25.5% | $5.5K | 2024-Q4 |
| SOUND SHORE MANAGEMENT INC /CT/ | EXIT | 1,140,812 | 0 | -100.0% | $0.00 | 2024-Q4 |
| RENAISSANCE TECHNOLOGIES LLC | EXIT | 967,153 | 0 | -100.0% | $0.00 | 2024-Q4 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | NEW | — | 12,208,668 | — | $767.7M | 2024-Q3 |
21 unique insiders with 5 transactions. Net insider value: -$338.0M ($0.00 bought, $338.0M sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| May 31, 2026 | Compton-Phillips Amy | EVP, Chief Medical Officer | F | 7,618 | $90.98 | $693.1K |
| May 31, 2026 | Newman Brian | EVP, Chief Financial Officer | F | 2,478 | $90.98 | $225.4K |
| May 21, 2026 | ROBBINS LARRY | Director | SELL | 370,462 | $93.45 | $34.6M |
| May 21, 2026 | ROBBINS LARRY | Director | SELL | 378,000 | $93.31 | $35.3M |
| May 21, 2026 | AGUIRRE FERNANDO | Director | D | 1,563 | $93.50 | $146.1K |
| May 20, 2026 | ROBBINS LARRY | Director | SELL | 797,628 | $93.48 | $74.6M |
| May 20, 2026 | AGUIRRE FERNANDO | Director | D | 30,437 | $93.78 | $2.9M |
| May 19, 2026 | ROBBINS LARRY | Director | SELL | 1,983,387 | $94.45 | $187.3M |
| May 14, 2026 | Shulman Douglas H. | Director | A | 1,447.504 | $97.15 | $140.6K |
| May 14, 2026 | BROWN C DAVID II | Director | A | 1,544 | $97.15 | $150.0K |
| May 14, 2026 | Finucane Anne A. | Director | A | 1,544.004 | $97.15 | $150.0K |
| May 14, 2026 | DECOUDREAUX ALECIA A | Director | A | 1,447.504 | $97.15 | $140.6K |
| May 14, 2026 | SANSONE GUY P | Director | A | 1,447 | $97.15 | $140.6K |
| May 14, 2026 | Norwalk Leslie V | Director | A | 1,447 | $97.15 | $140.6K |
| May 14, 2026 | KIRBY J SCOTT | Director | A | 1,447 | $97.15 | $140.6K |
| May 14, 2026 | Balser Jeffrey R. | Director | A | 2,058 | $97.15 | $199.9K |
| May 14, 2026 | AGUIRRE FERNANDO | Director | A | 1,563 | $97.15 | $151.8K |
| May 14, 2026 | Mahoney Michael F | Director | A | 1,737.005 | $97.15 | $168.7K |
| May 14, 2026 | Gallina John E | Director | A | 1,447.504 | $97.15 | $140.6K |
| May 14, 2026 | ROBBINS LARRY | Director | A | 1,930.005 | $97.15 | $187.5K |
| May 8, 2026 | Mandadi Tilak | EVP, Chief Exp & Tech Officer | SELL | 69,551 | $89.58 | $6.2M |
| Apr 1, 2026 | Clark James David | SVP, Cont & Chief Acct Officer | F | 3,262 | $72.49 | $236.5K |
| Apr 1, 2026 | CAPOZZI HEIDI B | EVP and Chief People Officer | F | 1,334 | $72.49 | $96.7K |
| Apr 1, 2026 | Nelson Steven H | EVP and President, Aetna | F | 2,432 | $72.49 | $176.3K |
| Apr 1, 2026 | Joyner J. David | President, CEO and Chair | F | 8,029 | $72.49 | $582.0K |
| Apr 1, 2026 | Khichi Samrat S. | EVP, CPO and General Counsel | F | 3,541 | $72.49 | $256.7K |
| Apr 1, 2026 | Mandadi Tilak | EVP, Chief Exp & Tech Officer | F | 3,634 | $72.49 | $263.4K |
| Apr 1, 2026 | Shah Prem S | EVP and Group President | F | 1,484 | $72.49 | $107.6K |
| Mar 31, 2026 | Compton-Phillips Amy | EVP, Chief Medical Officer | A | 35,928 | $71.82 | $2.6M |
| Mar 31, 2026 | Compton-Phillips Amy | EVP, Chief Medical Officer | A | 5,569 | $71.82 | $400.0K |
| Mar 31, 2026 | Mandadi Tilak | EVP, Chief Exp & Tech Officer | A | 22,277 | $71.82 | $1.6M |
| Mar 31, 2026 | Joyner J. David | President, CEO and Chair | A | 86,326 | $71.82 | $6.2M |
| Mar 31, 2026 | Mandadi Tilak | EVP, Chief Exp & Tech Officer | A | 143,712 | $71.82 | $10.3M |
| Mar 31, 2026 | CAPOZZI HEIDI B | EVP and Chief People Officer | A | 10,025 | $71.82 | $720.0K |
| Mar 31, 2026 | CAPOZZI HEIDI B | EVP and Chief People Officer | A | 64,670 | $71.82 | $4.6M |
| Mar 31, 2026 | Clark James David | SVP, Cont & Chief Acct Officer | A | 11,138 | $71.82 | $799.9K |
| Mar 31, 2026 | Khichi Samrat S. | EVP, CPO and General Counsel | A | 80,838 | $71.82 | $5.8M |
| Mar 31, 2026 | Clark James David | SVP, Cont & Chief Acct Officer | A | 11,976 | $71.82 | $860.1K |
| Mar 31, 2026 | Nelson Steven H | EVP and President, Aetna | A | 22,277 | $71.82 | $1.6M |
| Mar 31, 2026 | Khichi Samrat S. | EVP, CPO and General Counsel | A | 12,531 | $71.82 | $900.0K |
| Mar 31, 2026 | Nelson Steven H | EVP and President, Aetna | A | 143,712 | $71.82 | $10.3M |
| Mar 31, 2026 | Newman Brian | EVP, Chief Financial Officer | A | 19,493 | $71.82 | $1.4M |
| Mar 31, 2026 | Shah Prem S | EVP and Group President | A | 25,062 | $71.82 | $1.8M |
| Mar 31, 2026 | Shah Prem S | EVP and Group President | A | 161,676 | $71.82 | $11.6M |
| Mar 31, 2026 | Newman Brian | EVP, Chief Financial Officer | A | 125,748 | $71.82 | $9.0M |
| Mar 19, 2026 | Gallina John E | Director | A | 582 | $71.86 | $41.8K |
| Feb 28, 2026 | Khichi Samrat S. | EVP, CPO and General Counsel | F | 7,886 | $79.60 | $627.7K |
| Feb 28, 2026 | Joyner J. David | President and CEO | F | 1,944 | $79.90 | $155.3K |
10 SEC filing reports analyzed. Sentiment: 2 bullish, 1 bearish, 0 mixed, 7 neutral. Avg impact: 3.6/10.
NEUTRAL
COURT-RULING
3/10
The court denied Epic's motions to dismiss in eight of eleven complaints in the Generic Pharmaceutic
Jun 3, 2026
NEUTRAL
COURT-RULING
2/10
A Florida federal magistrate judge granted a motion to remand a slip-and-fall case against a CVS sto
May 28, 2026
NEUTRAL
S-3ASR
3/10
CVS Health filed an automatic shelf registration (S-3ASR) to register an indeterminate amount of deb
May 22, 2026
NEUTRAL
COURT-RULING
1/10
California Court of Appeal affirmed a complete defense verdict for CVS in a customer lawsuit allegin
May 19, 2026
BULLISH
COURT-RULING
6/10
The Ninth Circuit affirmed the district court's order compelling independent community pharmacies to
May 15, 2026
NEUTRAL
COURT-RULING
2/10
A federal district court in Illinois partially granted and partially denied CVS Health's motion to d
May 15, 2026
BULLISH
8-K
8/10
CVS Health reported strong Q1 2026 results with Adjusted EPS of $2.57, significantly beating the $2.
May 6, 2026
BEARISH
COURT-RULING
4/10
The D.C. Circuit Court of Appeals reversed a lower court's summary judgment in favor of CVS Pharmacy
Apr 21, 2026
NEUTRAL
COURT-RULING
3/10
The D.C. Circuit Court of Appeals reversed a lower court's summary judgment in favor of CVS in a sli
Apr 14, 2026
NEUTRAL
DEFA14A
4/10
CVS Health is holding its 2026 annual shareholder meeting to vote on director elections, auditor rat
Apr 3, 2026
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Current analyst consensus: Strong Buy (82% buy). Based on 33 analysts: 8 strong buy, 19 buy, 6 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$103.04 mean target
+7.4% upside
Buy (1.50)
$79.00 Low
$140.00 High
| Metric | Value |
|---|---|
| Current Price | $95.93 |
| Target Low | $79.00 |
| Target Mean | $103.04 |
| Target Median | $104.50 |
| Target High | $140.00 |
| # Analysts | 26 |
| Recommendation | Buy (1.50) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current FY 2026-12-31 |
$7.43 | $7.35 | $7.65 | 10.1% | +3.8% | 21↑ 0↓ | $409.2B | 1.8% | 23 |
| Current Q 2026-06-30 |
$1.83 | $1.48 | $1.94 | 1.0% | +2.0% | 15↑ 2↓ | $100.1B | 1.2% | 20 |
| Next Q 2026-09-30 |
$1.71 | $1.56 | $1.90 | 7.0% | -5.8% | 3↑ 14↓ | $103.5B | 0.6% | 20 |
| Next FY 2027-12-31 |
$8.37 | $8.07 | $8.80 | 12.7% | +2.0% | 22↑ 0↓ | $425.8B | 4.0% | 27 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $1.828 | |
| 7d ago | $1.825 | +0.003 |
| 30d ago | $1.792 | +0.036 |
| 60d ago | $1.829 | -0.001 |
| 90d ago | $1.827 | +0.001 |
17 analyst firms have rated this stock: 3 upgrades, 0 downgrades, 1 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Jun 4, 2026 | Morgan Stanley | MAINTAIN | Overweight | Overweight |
| Jun 1, 2026 | Truist Securities | MAINTAIN | Buy | Buy |
| May 26, 2026 | Barclays | MAINTAIN | Overweight | Overweight |
| May 20, 2026 | Mizuho | MAINTAIN | Outperform | Outperform |
| May 14, 2026 | Morgan Stanley | MAINTAIN | Overweight | Overweight |
| May 13, 2026 | Bernstein | MAINTAIN | Outperform | Outperform |
| May 12, 2026 | JP Morgan | MAINTAIN | Overweight | Overweight |
| May 11, 2026 | TD Cowen | MAINTAIN | Buy | Buy |
| May 8, 2026 | Wells Fargo | MAINTAIN | Overweight | Overweight |
| May 7, 2026 | UBS | MAINTAIN | Buy | Buy |
| May 7, 2026 | RBC Capital | MAINTAIN | Outperform | Outperform |
| May 7, 2026 | Barclays | MAINTAIN | Overweight | Overweight |
| May 7, 2026 | Truist Securities | MAINTAIN | Buy | Buy |
| May 7, 2026 | Evercore ISI Group | MAINTAIN | Outperform | Outperform |
| Apr 15, 2026 | Baird | MAINTAIN | Outperform | Outperform |
| Mar 31, 2026 | Piper Sandler | MAINTAIN | Overweight | Overweight |
| Mar 12, 2026 | Bernstein | UPGRADE | Market Perform | Outperform |
| Jan 28, 2026 | Argus Research | MAINTAIN | Buy | Buy |
| Jan 27, 2026 | B of A Securities | MAINTAIN | Buy | Buy |
| Jan 6, 2026 | Bernstein | MAINTAIN | Market Perform | Market Perform |
| Dec 17, 2025 | JP Morgan | MAINTAIN | Overweight | Overweight |
| Dec 12, 2025 | Bernstein | MAINTAIN | Market Perform | Market Perform |
| Dec 10, 2025 | Truist Securities | MAINTAIN | Buy | Buy |
| Dec 10, 2025 | Piper Sandler | REITERATE | Overweight | Overweight |
| Dec 10, 2025 | UBS | MAINTAIN | Buy | Buy |
| Dec 10, 2025 | Barclays | MAINTAIN | Overweight | Overweight |
| Dec 10, 2025 | Mizuho | MAINTAIN | Outperform | Outperform |
| Dec 10, 2025 | Morgan Stanley | MAINTAIN | Overweight | Overweight |
| Dec 10, 2025 | Baird | MAINTAIN | Outperform | Outperform |
| Dec 5, 2025 | Bernstein | MAINTAIN | Market Perform | Market Perform |
| Nov 13, 2025 | Wells Fargo | MAINTAIN | Overweight | Overweight |
| Nov 3, 2025 | TD Cowen | MAINTAIN | Buy | Buy |
| Oct 30, 2025 | Evercore ISI Group | MAINTAIN | Outperform | Outperform |
| Oct 30, 2025 | RBC Capital | MAINTAIN | Outperform | Outperform |
| Oct 30, 2025 | Cantor Fitzgerald | MAINTAIN | Overweight | Overweight |
| Oct 30, 2025 | Truist Securities | REITERATE | Buy | Buy |
| Oct 24, 2025 | UBS | MAINTAIN | Buy | Buy |
| Oct 14, 2025 | Morgan Stanley | MAINTAIN | Overweight | Overweight |
| Oct 14, 2025 | Goldman Sachs | INITIATE | — | Buy |
| Oct 9, 2025 | Mizuho | MAINTAIN | Outperform | Outperform |
| Oct 7, 2025 | Wells Fargo | MAINTAIN | Overweight | Overweight |
| Sep 22, 2025 | Evercore ISI Group | MAINTAIN | Outperform | Outperform |
| Sep 5, 2025 | Bernstein | MAINTAIN | Market Perform | Market Perform |
| Sep 4, 2025 | Barclays | MAINTAIN | Overweight | Overweight |
| Aug 26, 2025 | Cantor Fitzgerald | REITERATE | Overweight | Overweight |
| Aug 18, 2025 | UBS | UPGRADE | Neutral | Buy |
| Aug 14, 2025 | Baird | UPGRADE | Neutral | Outperform |
| Aug 1, 2025 | Morgan Stanley | MAINTAIN | Overweight | Overweight |
| Aug 1, 2025 | Barclays | MAINTAIN | Overweight | Overweight |
| Jul 22, 2025 | UBS | MAINTAIN | Neutral | Neutral |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 8 | 19 | 6 | 0 | 0 | 82% | |
| May 1, 2026 | 8 | 18 | 7 | 0 | 0 | 79% | |
| Apr 1, 2026 | 8 | 18 | 7 | 0 | 0 | 79% | |
| Mar 1, 2026 | 7 | 18 | 8 | 0 | 0 | 76% | |
| Feb 1, 2026 | 7 | 19 | 7 | 0 | 0 | 79% | |
| Jan 1, 2026 | 7 | 19 | 7 | 0 | 0 | 79% |
Strong BuyBuyHoldSellStrong Sell
4 members of Congress traded this stock: 3 buys, 2 sells.
Congressional Trades
| Date | Member | Party | Chamber | Type | Amount | Asset | Disclosed |
|---|---|---|---|---|---|---|---|
| Apr 13, 2026 | Ro Khanna | D | HOUSE | BUY | $1,001 - $15,000 | CVS Health Corp | May 13, 2026 (31d) |
| Feb 20, 2026 | Michael McCaul | R | HOUSE | BUY | $15,001 - $50,000 | CVS Health Corp | Mar 12, 2026 (21d) |
| Jan 29, 2026 | John Boozman | R | SENATE | BUY | $1,001 - $15,000 | CVS Health Corp | Feb 15, 2026 (18d) |
| Jan 13, 2026 | Michael McCaul | R | HOUSE | SELL | $15,001 - $50,000 | CVS Health Corp | Feb 12, 2026 (31d) |
| Nov 21, 2025 | Dwight Evans | D | HOUSE | SELL | $1,001 - $15,000 | CVS Health Corp | May 18, 2026 (179d) |
61°
Warm
Bearish
Neutral
Bullish
14 mentions
5 bullish
1 bearish
12 time periods
Reddit Sentiment History
| Date | Mentions | Sentiment | Bullish | Bearish | Threads |
|---|---|---|---|---|---|
| May 14, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| May 14, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| May 6, 2026 | 1 | 40° Cool | 0 | 1 | 1 |
| Apr 28, 2026 | 1 | 50° Neutral | 0 | 0 | 1 |
| Apr 28, 2026 | 1 | 50° Neutral | 0 | 0 | 1 |
| Mar 26, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| Mar 26, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| Mar 19, 2026 | 2 | 50° Neutral | 0 | 0 | 2 |
| Mar 19, 2026 | 2 | 50° Neutral | 0 | 0 | 2 |
| Mar 2, 2026 | 1 | 56° Neutral | 0 | 0 | 1 |
| Mar 2, 2026 | 1 | 56° Neutral | 0 | 0 | 1 |
| Feb 21, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
Recent Reddit Threads
CVS Health Q1 Earnings Call Live Transcript
▲ 1
💬 0
⚡ 0.5
United Health and CVS Wash rules
▲ 1
💬 1
⚡ 0.5
United Health and CVS Wash Rules
▲ 1
💬 0
⚡ 0.5
CVS !!! Let’s go !!!
▲ 1
💬 0
⚡ 0.5
Turning $40,000 to $400,000
▲ 1
💬 0
⚡ 0.5
Jun 5, 2026
short_volume
Short Volume: CVS — 60.7% short (2.1M / 3.5M)
Short: 2,121,404 | Exempt: 39,247 | TRF Vol: 3,496,539 | Short Ratio: 60.7% | Off-exchange volume (dark pool + OTC)
May 19, 2026
Enforcement
Yessian v. Garfield Beach CVS CA2/3
Court ruling from California Court of Appeal. Docket: B343942
May 15, 2026
Enforcement
Osterhaus Pharmacy, Inc. v. Cvs Health Corporation
Court ruling from Court of Appeals for the Ninth Circuit. Docket: 25-1843
May 14, 2026
short_volume
Short Volume: CVS — 59.5% short (2.3M / 3.8M)
Short: 2,251,441 | Exempt: 28,438 | TRF Vol: 3,784,636 | Short Ratio: 59.5% | Off-exchange volume (dark pool + OTC)
May 12, 2026
short_volume
Short Volume: CVS — 58.7% short (3.2M / 5.5M)
Short: 3,232,736 | Exempt: 55,907 | TRF Vol: 5,507,269 | Short Ratio: 58.7% | Off-exchange volume (dark pool + OTC)
May 11, 2026
short_volume
Short Volume: CVS — 55.4% short (2.6M / 4.7M)
Short: 2,605,656 | Exempt: 45,126 | TRF Vol: 4,701,053 | Short Ratio: 55.4% | Off-exchange volume (dark pool + OTC)
May 11, 2026
dark_pool
Dark Pool: CVS — 15.3M shares, 177,692 trades
Week starting 2026-05-11. Total ATS volume: 15,330,018 shares across 177,692 trades.
May 6, 2026
earnings_calendar
CVS Q1 2026 Earnings Before Market Open — 2026-05-06
May 4, 2026
dark_pool
Dark Pool: CVS — 12.4M shares, 156,785 trades
Week starting 2026-05-04. Total ATS volume: 12,391,005 shares across 156,785 trades.
Apr 29, 2026
short_volume
Short Volume: CVS — 58.4% short (1.5M / 2.5M)
Short: 1,450,014 | Exempt: 16,987 | TRF Vol: 2,481,115 | Short Ratio: 58.4% | Off-exchange volume (dark pool + OTC)
Apr 29, 2026
Enforcement
Eduardo Cuesta v. Holiday CVS, LLC d/b/a CVS Pharmacy Y Mas (Store #3706)
Court ruling from District Court, S.D. Florida. Docket: 1:25-cv-25695
Apr 27, 2026
dark_pool
Dark Pool: CVS — 7.3M shares, 121,330 trades
Week starting 2026-04-27. Total ATS volume: 7,326,370 shares across 121,330 trades.
Apr 20, 2026
dark_pool
Dark Pool: CVS — 8.8M shares, 114,717 trades
Week starting 2026-04-20. Total ATS volume: 8,763,893 shares across 114,717 trades.
Apr 14, 2026
Enforcement
Bruce Bunting v. District of Columbia CVS Pharmacy, LLC
Court ruling from Court of Appeals for the D.C. Circuit. Docket: 24-7124
Apr 14, 2026
Enforcement
Bruce Bunting v. District of Columbia CVS Pharmacy, LLC
Court ruling from Court of Appeals for the D.C. Circuit. Docket: 24-7124
Apr 13, 2026
dark_pool
Dark Pool: CVS — 9.0M shares, 124,151 trades
Week starting 2026-04-13. Total ATS volume: 8,982,304 shares across 124,151 trades.
Apr 10, 2026
short_volume
Short Volume: CVS — 56.9% short (1.0M / 1.8M)
Short: 1,005,621 | Exempt: 1,079 | TRF Vol: 1,768,057 | Short Ratio: 56.9% | Off-exchange volume (dark pool + OTC)
Apr 7, 2026
short_volume
Short Volume: CVS — 58.3% short (3.3M / 5.7M)
Short: 3,324,356 | Exempt: 19,740 | TRF Vol: 5,703,424 | Short Ratio: 58.3% | Off-exchange volume (dark pool + OTC)
Apr 6, 2026
short_interest
FTD: CVS — 49,261 shares ($3.6M) failed to deliver
Settlement: 20260406, Price: $73.49, FTD Value: $3,620,190.89, CVS HEALTH CORPORATION (DE)
Apr 6, 2026
dark_pool
Dark Pool: CVS — 8.6M shares, 117,901 trades
Week starting 2026-04-06. Total ATS volume: 8,595,795 shares across 117,901 trades.